Explore / Clinical trial
Clinical trial

Tolerance and Potential Synergistic Effect of the Combination of Intranasal Esketamine and Non-selective MAOI

University Hospital, Strasbourg, FranceCompletedStarted Apr 11, 202213 enrolledFranceNCT05530668

Abstract

There are already recently published data on the tolerability and efficacy of the combination of ketamine and/or esketamine with MAOIs. However, these reports are few and far between, and to our knowledge, there are no data involving intranasal esketamine. Given the numerous interactions between MAOIs and other antidepressants, and the impossibility of combination, this pharmacological class is neglected. This is despite the fact that MAOIs are the only truly tri-aminergic drugs, that they have unparalleled efficacy in certain forms of resistant apathetic depression, and that new, more dietary permissive forms have appeared on the market. The arrival of antidepressants that can be combined with MAOIs, such as ketamine and esketamine, changes the situation and could offer a new treatment opportunity to many patients in a therapeutic impasse. For these opportunities to become a reality, sharing the clinical experience gained by specialized centers is essential.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

KetamineDepressionAnxiety

Keywords

Depression DisorderAnxiety Disorderintranasal esketaminemonoamine oxidase inhibitors (MAOIs)MAOIsantidepressantsDepression Anxiety Disorder

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.